Tag Archives: CD70 CAR-T

CRISPR Tx, AZ, and MiNK Tx Report Data in Solid Tumors; AACR 2024 Analysis 1

AACR 2024 Analysis 1: CRISPR Tx, AZ and MiNK Tx presented clinical and preclinical updates from their programs in solid tumors. Below, Celltelligence provides insights and key context for selected presentations. The following topics are covered: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JPM 2024 Analysis Days 2 & 3: Imugene, CRISPR Tx, and Precigen

On the second and third days of JPM 2024, Celltelligence covered presentations by Imugene (webcast / presentation), CRISPR Tx (press release / webcast), and Precigen (webcast / presentation). Below, Celltelligence provides insights and context for each presentation. The following topics are covered: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 2

On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) featuring the advances in its hematology and solid tumor programs. Below, Celltelligence provides part 2 of its analysis on Allogene’s pipeline covering its expanded solid tumor franchise and initial clinical data from ALLO-316’s (allogeneic CD70 CAR-T) while comparing Allogene’s Dagger platform to other approaches for reducing immune rejection.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Poseida, CRISPR Tx, and Cellectis Present Novel Allogeneic CAR-T for Solid Tumors; SITC 2022 Analysis 1

SITC 2022 Analysis 1: Poseida, CRISPR Tx, and Cellectis presented preclinical and clinical updates from their allogeneic cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.